Pharosyn raises $3m in seed funding to expand its artificial intelligence platform for pharmaceutical companies.
Moonfire Ventures led the seed round for the London-based commercial intelligence startup.
≈ £2.2M at $1 = £0.7421 on 2 Sep 2026
London startup developing artificial intelligence systems for commercial departments in pharmaceutical companies.
London-based artificial intelligence startup Pharosyn has raised $3m in a seed round led by Moonfire Ventures, with participation from Entrepreneurs First, Transpose Platform, and General Advance.
The capital will be used to expand the team by hiring additional engineers and pharmaceutical industry specialists, scaling the company beyond its current workforce of 11 employees.
Pharosyn provides custom artificial intelligence tools designed for commercial and competitive intelligence teams within pharmaceutical companies, helping executives make faster decisions regarding pricing, market access, and portfolio strategy.
From the founder
"We reduced their time to produce a report or answer a question by 94%. Whereas before it was four hours to produce a report, senior executives were waiting hours and hours for an answer. We brought that down to a few minutes"
Stephen Cowley
Co-founder and CEO at Pharosyn
Investor perspective
"Pharosyn’s founders are deeply technical, exceptionally tenacious and ambitious, and determined to be best-in-class globally. They are rare founders who clearly stand out. We could not be more excited to lead this round."
Mattias Ljungman
Founder, Moonfire
Use of funds
- 01Grow the team
